A Phase 2 interventional study of NNZ-2591 in Prader-Willi Syndrome, sponsored by Neuren Pharmaceuticals Limited. Withdrawn at 4 sites in United States. Open to participants aged 4 Years to 12 Years. Per ClinicalTrials.gov, last updated 2024-12-09.
Sponsored by Neuren Pharmaceuticals Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Prader-Willi Syndrome with a site in United States — 9 open to participants now, 14 under way, 3 of them phase 3. Prader-Willi Syndrome · United States.
Among the 69 studies in Prader-Willi Syndrome with a site in United States, this one is the 56th largest by enrollment of the 58 interventional ones that give a count, is one of 7 that started in 2023, is one of 17 in phase 2, and was the 54th registered.
144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.
Browse Prader-Willi Syndrome studies →9 of the 69 studies in Prader-Willi Syndrome with a site in United States are open now. Recruiting first, the newest first:
Children's Mercy Hospital Kansas City · Sites in United States
Ages 13–17
ConSynance Therapeutics · Sites in United States
Ages 13–50
Grace Kim · Sites in United States
Ages 18–26
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+ · Healthy volunteers
Harmony Biosciences Management, Inc. · Sites in United States, Australia, Belgium and 10 more countries
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.
This study: 4 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 23 · Phase 3 16 · Phase 4 3
First in 1999; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 23 across the 58 interventional studies, 200 across the 11 observational. Of the 51 that completed or were terminated, 21 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 69 have an industry lead sponsor. The 10 most frequent:
Neuren Pharmaceuticals Limited is the lead sponsor of 15 studies on the registry; 2 are open to participants now.
Neuren Pharmaceuticals Limited has 1 study filed under Prader-Willi Syndrome — fewer than ten, so there is no comparison to draw.
7 of the studies in Prader-Willi Syndrome with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06366464Phase 3Harmony Biosciences Management, Inc.A Study of Pitolisant in Patients With Prader-Willi Syndrome | 2027-04 |
| NCT06144645Phase 3Foundation for Prader-Willi ResearchA Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS | 2027-04-01 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06239116Rhythm Pharmaceuticals, Inc.A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment | 2027-05-07 |
| NCT07348601ConSynance TherapeuticsA Study of CSTI-500 in Patients With Prader-Willi Syndrome | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 69 studies in Prader-Willi Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Prader-Willi Syndrome.
The primary purpose of this study is to investigate the safety, tolerability and pharmacokinetics of treatment with NNZ-2591 oral solution in children and adolescents with Prader-Willi Syndrome. The secondary purpose is to investigate measures of efficacy. Subjects will receive treatment with NNZ-2591 oral solution (50 mg/mL) doses for a total of 13 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
Drug: NNZ-2591
NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
Also known as: Cyclo-L-Glycyl-L-2-Allylproline
Safety and Tolerability
To examine the incidence, severity and frequency of adverse events (AEs), including serious adverse events (SAEs) during treatment with NNZ-2591.
Time frame: 13 weeks
Pharmacokinetic - Measurement of Cmax
Maximum observed concentration (Cmax) of NNZ-2591
Time frame: 13 weeks
Pharmacokinetic - Measurement of AUC
Area under the concentration-time curve of NNZ-2591
Time frame: 13 weeks
Pharmacokinetic - Measurement of time to Cmax
Time to Cmax of NNZ-2591
Time frame: 13 weeks
Pharmacokinetic - Measurement of t1/2
Apparent terminal elimination half-life of NNZ-2591
Time frame: 13 weeks
Exploratory efficacy measurement
Assessed by PWS-specific Clinical Global Impression Scale \& Domain -Overall Improvement Score (CGI-I)
Time frame: 13 weeks
Exploratory efficacy measurement
Assessed by Caregiver Global Impression-Change Score
Time frame: 13 weeks
Exploratory efficacy measurement
Assessed by PWS-specific Clinical Global Impression Scale-Severity (CGI-S) Overall Score
Time frame: 13 weeks
Exploratory efficacy measurement
Assessed by Caregiver Top 3 Concerns Likert Scale Scores
Time frame: 13 weeks
Exploratory efficacy measurement
Assessed by PWS Profile Score
Time frame: 13 weeks
Exploratory efficacy measurement
Assessed by PWS Anxiousness and Distress Behaviors Questionnaire Score (PADQ)
Time frame: 13 weeks
Exploratory efficacy measurement
Assessed by Autism Diagnostic Observation Schedule (ADOS-2), Repetitive behaviors and Social scores
Time frame: 13 weeks
Exploratory efficacy measurement
Assessed by Hyperphagia Questionnaire-Clinical Trials (HQ-CT) Score
Time frame: 13 weeks
Exploratory efficacy measurement
Assessed by Food Safety Zone Questionnaire Score
Time frame: 13 weeks
Exploratory efficacy measurement
Assessed by Vineland Adaptive Behavior Scales-3 Growth Scale Scores
Time frame: 13 weeks
Exploratory efficacy measurement
Assessed by Zarit Burden Interview Score
Time frame: 13 weeks
Exploratory efficacy measurement
Assessed by Child Sleep Habits Questionnaire (CSHQ)
Time frame: 13 weeks
Exploratory efficacy measurement
Assessed by Impact of Childhood Neurological Disability Scale (ICND)
Time frame: 13 weeks
Exploratory efficacy measurement
Assessed by Quality of Life Inventory-Disability (QI-Disability)
Time frame: 13 weeks
Exploratory efficacy measurement
Assessed by Kaufman Brief Intelligence Test or Mullen Scales of Early Learning
Time frame: 13 weeks
Exploratory efficacy measurement
Assessed by PWS Suicidality Assessment
Time frame: 13 weeks
Exploratory efficacy measurement
Assessed by Caregiver Diary
Time frame: 13 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Jun 2025, 21 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ercanetide
Neuren Pharmaceuticals Limited